Table 2

Schedule of outcome assessments for GaPP2

Phase	Run-in				Baseline, randomisation and treatment dispensed	Titration	Treatment					End of study and unblinding	Taper
Duration (weeks)	−4 to −1				0	1–4	5–12	13–16					17–19
Weekly worst and average NRS	x	x	x	x				x	x	x	x
SF-12					X							X
BPI					X							X
PCS					X							X
SAQ					X							X
BFI					X							X
GHQ					X							X
WPAIQ					X							X
PainDETECT					X							X
PUF					X
Adverse events						X	X	X				X	X
Permitted/concomitant medication	X					X	X	X					X
Adherence or discontinuation						X	X	X					X

BFI, Brief Fatigue Inventory; BPI, Brief Pain Inventory; GHQ, General Health Questionnaire; NRS, Numerical Rating Scale; PCS, Pain Catastrophising Scale; PUF, Pelvic Pain and Urinary/Frequency Patient Symptom Scale; SAQ, Sexual Activity Questionnaire; SF-12, 12-Item Short-Form Health Survey; WPAIQ, Work and Productivity Activity Impairment Questionnaire.